KevadBio
Financiado
Developing a novel Parkinson's disease drug using small molecule mimetics of Gli...
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)
GeneCode is developing a novel anti-PD drug that contains a central nervous system penetrant compound imitating GDNF peptide pathway activation that alleviates both motor and non-motor symptoms in PD patients, protecting and resto...
GeneCode is developing a novel anti-PD drug that contains a central nervous system penetrant compound imitating GDNF peptide pathway activation that alleviates both motor and non-motor symptoms in PD patients, protecting and restoring lesioned dopamine neurons as well as potentially increasing dopamine levels in brain tissue. GeneCode’s unique solution uses small-molecule compounds that penetrate the blood-brain barrier, target the GFL receptor complex (containing GDNF protein) and mimic GFL (GNDF family of ligands) biological effects in neurons, promoting survival in the affected dopaminergic neuronal pathways. Once fully developed, the PD drug would be administered weekly or less frequently as an oral treatment. Considering the importance of GDNF family ligands and/or RET-signalling pathways for other groups of cells, applications of compounds developed by GeneCode are not limited to PD, but can be applied to cure other medical conditions such as neuropathic pain, addiction, ALS etc.
ver más
Duración del proyecto: 25 meses
Fecha Inicio: 2023-11-17
Fecha Fin: 2025-12-31
Fecha Fin: 2025-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-17
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-ACCELERATOROPEN-01:
EIC Accelerator Open 2023
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
GENECODE AS
No se ha especificado una descripción o un objeto social para esta compañía.
